Suppr超能文献

遗传性血色素沉着症患者肝移植的结果

Outcome of liver transplantation in hereditary hemochromatosis.

作者信息

Dar Faisal S, Faraj Walid, Zaman Muhammad B, Bartlett Adam, Bomford Adrian, O'Sullivan Adrian, O'Grady John, Heneghan Michael, Rela Mohamed, Heaton Nigel D

机构信息

Kings College London School of Medicine, Institute of Liver Studies, Kings College Hospital, London, SE5 9RS, UK.

出版信息

Transpl Int. 2009 Jul;22(7):717-24. doi: 10.1111/j.1432-2277.2009.00863.x. Epub 2009 Mar 16.

Abstract

Hereditary hemochromatosis (HH) is a genetic disorder of iron metabolism. It is an uncommon indication for liver transplantation (LT). It has been suggested that patients who undergo LT for cirrhosis related to HH have higher morbidity and mortality from cardiac, infectious and malignant complications. The purpose of this retrospective review was to determine whether these observations hold true in the current era. We analysed the data of 22 patients who had LT for HH from 1996 to 2007 at our center. Thirteen patients had LT for complications of end-stage liver disease, seven for hepatocellular carcinoma (HCC) and two for subacute liver failure. Cofactors promoting liver disease were identified in 15 patients. Ten patients had iron reduction with venesection before transplantation. Patient and graft survival at 1 and 5 years were 80.7%, and 74% respectively. There were seven deaths after a median follow up of 46 months either because of multiorgan failure, or caused by HCC recurrence. Bacterial infections were the commonest cause of morbidity. Patients with HH remain at a higher risk of developing HCC. Infectious complications are common. Iron reduction with preoperative venesection reduces the risk of cardiac and infection complications postoperatively. Improved survival post-LT reflects changes in selection, disease modification through venesection, and improvement in immunosuppression.

摘要

遗传性血色素沉着症(HH)是一种铁代谢的遗传紊乱疾病。它是肝移植(LT)的一种罕见适应症。有人提出,因HH相关肝硬化接受LT的患者,因心脏、感染和恶性并发症导致的发病率和死亡率更高。本回顾性研究的目的是确定这些观察结果在当前时代是否仍然成立。我们分析了1996年至2007年在我们中心接受HH肝移植的22例患者的数据。13例患者因终末期肝病并发症接受LT,7例因肝细胞癌(HCC)接受LT,2例因亚急性肝衰竭接受LT。15例患者确定了促进肝病的辅助因素。10例患者在移植前通过放血进行了铁减少治疗。1年和5年时的患者及移植物生存率分别为80.7%和74%。中位随访46个月后,有7例死亡,原因是多器官衰竭或HCC复发。细菌感染是最常见的发病原因。HH患者发生HCC的风险仍然较高。感染并发症很常见。术前放血进行铁减少可降低术后心脏和感染并发症的风险。肝移植后生存率的提高反映了选择标准的改变、通过放血改善病情以及免疫抑制的改善。

文献AI研究员

20分钟写一篇综述,助力文献阅读效率提升50倍。

立即体验

用中文搜PubMed

大模型驱动的PubMed中文搜索引擎

马上搜索

文档翻译

学术文献翻译模型,支持多种主流文档格式。

立即体验